Related Experiment Video
Updated: Aug 16, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Brain metastases in breast cancer--an in vitro study to evaluate new systemic chemotherapeutic options
A Honig1, L Rieger, A Sutterlin
1Department of Obstetrics and Gynecology, University of Wuerzburg, Germany. arnd_hoenig@hotmail.com
Background:
Fifteen-30% of breast cancer patients develop central nervous system (CNS) metastases. The most potent drugs for the treatment of breast cancer like taxanes, anthracyclines and trastuzumab have limited efficacy for brain metastases. No standardized therapy has yet been established for this condition. Drugs with proven efficacy in the CNS and which are commonly used for primary brain tumors were applied. We evaluated the capacity of these drugs to inhibit breast tumor cell growth in vitro.
Materials And Methods:
Twelve primary cell cultures of pulmonary/pleural metastases of breast cancer and 3 commercially available cell lines were used for non-radioactive cytotoxicity assays to evaluate the efficacy of 3 different concentrations of Topotecan, Cisplatin, Nimustine, Vincristine, Irinothecan, Caelyx (pegylated liposomal Doxorubicin) and Etoposide.
Results:
Topotecan, Cisplatin, Caelyx and Vincristine showed significantly higher cytostatic activity in vitro than Irinotecan, Etoposide and Nimustine. With regard to the median cytotoxicity, the order of drugs in our assays was Topotecan, Cisplatin, Vincristine, Caelyx, Irinotecan, Etoposide and Nimustine. Nimustine showed almost no efficacy against breast cancer cells.
Conclusion:
Topotecan, Cisplatin, Vincristine and Caelyx seem to be suitable candidates for further clinical evaluation. The data and the "liposomal packaging" suggest that Caelyx might be effective in the CNS. Since pulmonary metastases are often associated with brain metastases, evaluatingprimary cell cultures from malignant pleural effusions could be a valuable approach for the testing of new cytostatic drugs for brain metastases.
Insights
Topotecan, Cisplatin, Vincristine, and Caelyx show promise for treating breast cancer brain metastases. These drugs demonstrated superior in vitro efficacy compared to others tested, suggesting potential for clinical evaluation.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis
Background:
- Central nervous system (CNS) metastases affect 15-30% of breast cancer patients.
- Standard therapies for brain metastases are lacking, and common breast cancer drugs show limited efficacy.
- Drugs used for primary brain tumors were investigated for their potential against breast cancer brain metastases.
Purpose of the Study:
- To evaluate the in vitro efficacy of several drugs against breast cancer cell growth.
- To identify potential therapeutic agents for CNS metastases from breast cancer.
Main Methods:
- Utilized 12 primary breast cancer cell cultures from pulmonary/pleural metastases and 3 commercial cell lines.
- Conducted non-radioactive cytotoxicity assays to test Topotecan, Cisplatin, Nimustine, Vincristine, Irinothecan, Caelyx (pegylated liposomal Doxorubicin), and Etoposide at three concentrations.
Main Results:
- Topotecan, Cisplatin, Caelyx, and Vincristine exhibited significantly higher in vitro cytostatic activity.
- The order of median cytotoxicity was Topotecan > Cisplatin > Vincristine > Caelyx > Irinotecan > Etoposide > Nimustine.
- Nimustine demonstrated minimal efficacy against breast cancer cells.
Conclusions:
- Topotecan, Cisplatin, Vincristine, and Caelyx are candidates for clinical evaluation in breast cancer brain metastases.
- Caelyx's liposomal formulation suggests potential CNS efficacy.
- Primary cell cultures from pleural effusions may serve as a valuable model for testing novel cytostatic drugs for brain metastases.
